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summARy – metastases to pituitary gland are unusual and mostly asymptomatic, presenting 
with local symptoms in one of ten patients, and only 3%-5% of them are of prostate origin. here 
we report and evaluate the effectiveness and safety of multimodal treatment in a patient with pi-
tuitary metastasis of a prostate foamy gland carcinoma. A 78-year-old male patient presented with 
blurred vision and headache without a previous history of malignancy. magnetic resonance imaging 
scans revealed a large sellar mass, with infiltration of the surrounding structures. maximal trans-
sphenoidal reduction of pituitary metastasis was performed, with a histologic finding of metastatic 
prostate foamy gland adenocarcinoma. evaluation of the prostate specific antigen revealed a very 
high level (1461 ng/ml) and foamy gland carcinoma was found on prostate needle biopsy. The 
patient received 3d conformal external beam radiotherapy with 6 mv photons to the sellar and 
parasellar region with a tumor dose of 44 gy, followed by androgen deprivation therapy. follow up 
magnetic resonance imaging done after radiotherapy showed shrinkage of the tumor process, with 
rapid prostate specific antigen decline to 0.3 ng/ml. The visual function was fully established and 
headache resolved. on the last follow up 14 months after the diagnosis, the patient was alive and 
free from clinical signs of disease. tailored treatment, including limited radiotherapy in a higher 
palliative dose, in a patient with foamy gland symptomatic pituitary metastatic disease resulted in 
good local and systemic control of the disease. In older male patients with clinical and/or radiologic 
characteristics suggestive of metastatic pituitary disease, the prostate specific antigen test should be 
included as part of the work-up.
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Introduction
metastases to pituitary gland (pm) are unusual and 
mostly asymptomatic, with local symptoms present in 
one of ten patients. metastases are microscopic and of-
ten undetectable with current imaging techniques1,2. 
Breast and lung cancer account for two-thirds of pm, 
and other tumor types are sporadically detected, with 
only 3%-5% of prostate origin2,3. symptomatic pm pa-
tients are often diagnosed at an advanced stage, with 
additional metastatic sites, although cases of solitary 
pm have been described1,4. Also, several very common 
benign conditions can mimic metastatic carcinoma4.
In pm patients, palliative multidisciplinary ap-
proach is necessary, with local (surgery ± radiothera-
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py, Rt) and systemic options of treatment (hormonal 
therapy, chemotherapy, targeted therapies), depend-
ing on the primary tumor site and metastatic disease 
extent1. median survival of pm patients is 6 months, 
and the majority of these patients will not live long 
enough to develop specific side effects of treatment. 
however, in some patients, longer survival was ob-
served, requiring adjustment of treatment strategy2,5. 
here we report on a patient with symptomatic pm 
as the first sign of disseminated prostate foamy gland 
carcinoma, with good treatment response, and discuss 
optimal palliative treatment strategy and clinical/ra-
diological characteristics of pm.
Case Report
A 78-year-old Caucasian patient with double and 
blurred vision, headache, dizziness and nausea, with-
out a previous history of malignancy, was admitted 
for diagnostic work-up. magnetic resonance imaging 
(mRI) scans revealed a large sellar mass, 45x41x33 
mm in size, with infiltration of both cavernous si-
nuses and spreading to the suprasellar cisternal space, 
optic chiasm, sphenoidal sinus and ethmoid, without 
brain metastases. Computed tomography (Ct) scan 
showed destruction of the sphenoid sinus walls, pos-
terior part of the ethmoid bone, both perpendicular 
plates of the palatine bone, clivus, apex of the left and 
right pyramid, and left medial pterygoid plate. mag-
netic resonance angiography 3d time of flight (mRA 
3d tof) showed widening of the circle of willis and 
displacement of A1 segment of the anterior cerebral 
artery (fig. 1). 
The patient did not experience signs of diabetes 
insipidus. Results of initial endocrinological evalua-
tion are shown in table 1. maximal transsphenoidal 
Fig. 1. Preoperative radiographic images: (A) computed tomography scan in bone window; (B) magnetic resonance 
imaging (MRI)-enhanced T1WI scan in axial plane; (C) MRI-enhanced T1WI in coronal plane; (D) MRI 
preoperative T2 scan in sagittal plane; (E) MRI-T2 scan in coronal plane; (F) magnetic resonance angiography 3D 
time of flight.
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reduction of pm was performed. histology specimen 
of the pituitary tumor showed clusters of foamy cells 
with small and hyperchromatic nuclei, and minute 
glandular structures were sporadically formed. Im-
munohistochemical analysis was performed and the 
diagnosis of metastatic prostate foamy gland adeno-
carcinoma was established (fig. 2). diagnostic work-
up showed a very high prostate specific antigen (psA) 
level (1461 ng/ml; reference range: 0-4 ng/ml), and 
cervical and lumbar spine metastases were detected on 
bone scan. on prostate needle biopsy, a foamy gland 
carcinoma gleason grade 7 (4+3), histologically simi-
lar to the pituitary metastatic tumor, was found. Can-
cer was found in three of ten cores from both prostate 
lobes, with maximal 30% core involvement. mRI of 
the sellar and parasellar region done before radiother-
apy showed a residual tumor mass, 27x11 mm in size, 
with infiltration of the right cavernous sinus. 
The patient received 3d-conformal Rt with 6 
mv photons to the sellar and parasellar region with 
a tumor dose of 44 gy in 22 fractions (2.0 gy/frac-
tion, five times a week). The doses to the organs at 
risk were 43 gy, with dmax 45 gy to the optic chi-
asm, and dmax of 45 and 44 gy to the optic nerves 
(left/right). hormonal therapy with an lh-Rh ago-
Table 1. Results of initial endocrinological evaluation
































lh = luteinizing hormone; fsh = follicle-stimulating hormone; 
tsh = thyroid-stimulating hormone; t3 = triiodothyronine; t4 = 
thyroxine; ACth = adrenocorticotropic hormone; gh = human 
growth hormone; pRl = prolactin
Fig. 2. Histologic examination of removed tissue: (A) pituitary osteoblastic metastasis of the prostatic foamy gland 
carcinoma (H&E stain, X200); (B) primary tumor site: clusters of foamy gland carcinoma cells in prostatic needle 
biopsy. (H&E stain, X200) 
Fig. 3. Follow-up radiographic images (magnetic 
resonance imaging): (A) early postoperative enhanced 
T1 in coronal plane (inserted fat in postoperative area); 
(B) post-radiotherapy enhanced T1 in coronal plane 
(shrinkage).
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nist (leuprolide acetate, 22.5 mg) was introduced with 
the oral nonsteroidal antiandrogen flutamide, at the 
beginning of lh-Rh therapy to prevent flare or tu-
mor compression to the spinal cord and optic nerves/
chiasm. The lh-Rh agonist was administered every 
three months. This therapy resulted in regression of 
clinical symptoms, with fully recovered visual func-
tion and resolution of headache. follow up mRI done 
after Rt showed shrinkage of the tumor (fig. 3), 
while psA level declined rapidly to 0.3 ng/ml. on 
the last follow up 14 months after the diagnosis, the 
patient was alive and free from any clinical signs of 
the disease. 
Discussion
pituitary metastases are rarely reported, with data 
mostly collected from historical autopsy series with 
only few symptomatic cases reported4,6. The most fre-
quent clinical and radiological features of pm, and 
characteristics of the patient are shown in table 27. 
due to many similar features, pm can be mistaken 
for a much more common pituitary adenoma, and 
sometimes only pathological report gives the right 
diagnosis. however, clinical diagnosis of pm can 
be made with a combination of diagnostic features. 
foamy gland carcinoma is a variant of prostatic acinar 
adenocarcinoma characterized by abundant, foamy 
cytoplasm, typically small and hyperchromatic nuclei, 
and minimal cytologic atypia8. foamy gland carci-
noma is mostly admixed with the usual acinar adeno-
carcinoma and the pure foamy gland form is relatively 
uncommon. This histologic variant of prostatic ade-
nocarcinoma is often associated with indolent clinical 
behavior, but some patients having cancer with ag-
gressive biological behavior could be classified as an 
intermediate-grade cancer9. 
symptomatic metastatic pm often infiltrates sur-
rounding structures and total removal of the tumor is 
usually not feasible2. Therefore, postoperative pallia-
tive Rt must be included whenever possible to im-
prove the local control rate. Rt can be delivered to 
a limited (Rt to the sellar and parasellar region, to 
pituitary fossa, and stereotactic Rt) or extended area 
(whole brain Rt with/without boost to the pituitary 
fossa)10. A limited radiation field could result in reduc-
tion in the grade and severity of side effects, but with 
the possible higher percentage of treatment failures, 
while extended radiation could provide eradication of 
microscopic disease with the burden of toxicity. Syn-
chronous brain parenchyma metastases are not com-
mon in pm patients11, so whole brain Rt could be 
omitted, especially in patients with smaller tumors. 
The maximum radiation dose delivered to the 
tumor is limited by the surrounding tissue radiation 
tolerance. The radiation-induced optic neuropathy 
develops in the time frame of 1-2.5 years12. how-
ever, some studies have reported that the radiation 
tolerance threshold could be lower in patients with 
pituitary tumors vs. non-pituitary targets, with com-
plications occurring at low doses of 46 gy (1.8 gy/
fraction), and dmax 46 and 45 gy. The risk of nerve 
injury was increased with a larger fraction size (>2 gy), 
and a median period of latency of only 10.5 months 
was observed in patients with pm13-16. The majority 
of data on Rt to pituitary gland are collected from 
radiotherapy of pituitary adenomas, administered for 
tumor mass and hypersecretion reduction, usually at 
a median total dose >50 gy in smaller fractions (≤2 
gy)16. palliative Rt doses to the brain are commonly 
delivered at a schedule of 30 gy (3 gy/fraction, five 
times a week), and this dose can be sufficient in some 
patients. however, a schedule of 44 gy delivered in 2 
gy daily fractions, dmax of organs at risk, is below 
the threshold and a higher palliative radiation dose is 
delivered.
The level of psA can be elevated, or even within 
the reference range in metastatic pituitary disease17. 
Table 2. Clinical and radiological patient characteristics 
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Caution is needed on interpretation because psA lev-
els can also be elevated in non-prostatic malignant dis-
ease18. however, highly elevated psA levels are sug-
gestive of active malignant prostatic disease, and rapid 
fall of these values to almost undetectable levels could 
predict good treatment response. low testosterone 
level as a result of pituitary dysfunction19 could work 
synergistically with lh-Rh, and shorten the time to 
achieve chemical castration. tailored multimodality 
treatment, including limited Rt at a higher palliative 
dose, in our patient with foamy gland prostate car-
cinoma with upfront pituitary metastasis resulted in 
good local and systemic control of the disease, with 
minimizing the risk of radiation-induced optic neu-
ropathy. In older male patients with clinical and/or 
radiological characteristics suggestive of metastatic 
pituitary disease, the psA test should be included as 
part of the work-up.
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sažetak
InICIJAlno otKRIvenA sImptomAtsKA metAstAZA u hIpofIZu u BolesnIKA s 
KARCInomom pRostAte pJenuŠAvIh stAnICA: odReĐIvAnJe sIguRne I efIKAsne 
teRApIJe
M. Prpić, A. Fröbe, D. Zadravec, L. Pažanin, B. Jakšić, A. Bolanča i Z. Kusić
metastaze u hipofizu su vrlo rijetke, a oko 3%-5% čine metastaze s ishodištem u prostati, u većini slučajeva su asimp-
tomatske, dok su lokalni simptomi prisutni samo u jednog od deset bolesnika. ovim slučajem prikazujemo i procjenjujemo 
učinkovitost i sigurnost multimodalnog liječenja u bolesnika s metastazama u hipofizu primarnog ishodišta u karcinomu 
prostate pjenušavih stanica. prikazuje se 78-godišnji muškarac bez prethodne anamneze maligne bolesti kod kojega su se 
pojavili simptomi zamućenog vida i glavobolje. magnetskom rezonancom je otkrivena velika selarna masa s infiltracijom 
okolnih struktura. učinjena je maksimalna transfenoidna redukcija metastaze u hipofizi te je dobiven histološki nalaz 
metastatskog adenokarcinoma prostate pjenušavih stanica. otkrivena je vrlo visoka vrijednost za prostatu specifičnog an-
tigena (1461 ng/ml) te je biopsijom prostate tankom iglom dobiven nalaz karcinoma pjenušavih stanica. Bolesnik je primio 
3d-konformalnu radioterapiju vanjskim snopom s fotonima energije 6 mv na selarnu i paraselarnu regiju s tumorskom 
dozom od 44 gy te je nastavio primati androgenu deprivacijsku terapiju. Kontrolna snimka magnetske rezonance pokazala 
je smanjenje tumorskog procesa s brzim padom za prostatu specifičnog antigena na 0,3 ng/ml. uspostavljena je potpuna 
vizualna funkcija s postupnim nestankom glavobolje. na posljednjem kontrolnom pregledu 14 mjeseci nakon postavljene 
dijagnoze bolesnik je živ, bez kliničkih znakova bolesti. prilagođeno liječenje bolesnika sa simptomatskom metastatskom 
bolesti od karcinoma pjenušavih stanica, koje uključuje ograničenu radioterapiju u višoj palijativnoj dozi, rezultiralo je 
dobrom lokalnom i sistemskom kontrolom bolesti. u starijih muških bolesnika s kliničkim i/ili radiološkim osobinama sa 
sumnjom za metastatsku bolest u hipofizu test za prostatu specifičnog antigena trebao bi biti uključen kao dio obrade.
Ključne riječi: Antigen specifičan za prostatu; Prostata, tumori; Radioterapija; Hipofiza, tumori; Tumorska metastaza
